Literature DB >> 25757686

Pancreatic neuroendocrine tumors: a review.

Kate Young1, Ridhima Iyer, Daniel Morganstein, Ian Chau, David Cunningham, Naureen Starling.   

Abstract

Neuroendocrine tumors (NETs) are a rare and heterogeneous group of tumors with widely varying morphologies and behaviors. Due to their rarity and heterogeneity, progress in improving their treatment has been slow. However, in recent years there have been advances both in their characterization and in the available treatment options. This review will attempt to address these, with particular reference to pancreatic NETs. Pancreatic NETs are a subset of NETs, previously known as islet cell tumors, which appear to be a distinct biological entity, responding differently to systemic treatments compared with NETs arising elsewhere in the GI tract.

Entities:  

Keywords:  DOTATATE; NETs; everolimus; neuroendocrine tumors; octreotide; pNETs; pancreatic NETs; somatostatin analogs; sunitinib

Mesh:

Year:  2015        PMID: 25757686     DOI: 10.2217/fon.14.285

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  13 in total

Review 1.  The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.

Authors:  Shilpa Thakur; Brianna Daley; Joanna Klubo-Gwiezdzinska
Journal:  J Mol Endocrinol       Date:  2019-08       Impact factor: 5.098

2.  Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report.

Authors:  Reza Ershadi; Matin Vahedi; Behnaz Jahanbin; Javad Sarbazzadeh; Shahab Rafieian
Journal:  Int Cancer Conf J       Date:  2022-02-23

3.  A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors.

Authors:  Apostolos Gaitanidis; Dhaval Patel; Naris Nilubol; Amit Tirosh; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

Review 4.  Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Authors:  Sergio Pedraza-Arévalo; Manuel D Gahete; Emilia Alors-Pérez; Raúl M Luque; Justo P Castaño
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 5.  Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Authors:  Qun Chen; Wu-Jun Wang; Yun-Xuan Jia; Hao Yuan; Peng-Fei Wu; Wan-Li Ge; Ling-Dong Meng; Xu-Min Huang; Peng Shen; Tao-Yue Yang; Yi Miao; Jing-Jing Zhang; Kui-Rong Jiang
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

6.  A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).

Authors:  Antonio Viúdez; Filipe L F Carvalho; Zahra Maleki; Marianna Zahurak; Daniel Laheru; Alejandro Stark; Nilofer S Azad; Christopher L Wolfgang; Stephen Baylin; James G Herman; Ana De Jesus-Acosta
Journal:  Oncotarget       Date:  2016-05-03

7.  Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection.

Authors:  Dezhi Li; Yu Zhou; Yanhui Liu; Ye Lin; Min Yu; Xin Lu; Bowen Huang; Zhonghai Sun; Zhixiang Jian; Baohua Hou
Journal:  Onco Targets Ther       Date:  2018-03-06       Impact factor: 4.147

8.  Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

Authors:  Amira Mohamed; David Romano; Alexandru Saveanu; Catherine Roche; Manuela Albertelli; Federica Barbieri; Thierry Brue; Patricia Niccoli; Jean-Robert Delpero; Stephane Garcia; Diego Ferone; Tullio Florio; Vincent Moutardier; Flora Poizat; Anne Barlier; Corinne Gerard
Journal:  Oncotarget       Date:  2017-06-20

Review 9.  Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review.

Authors:  Chunhui Zhang; Jingchun Zhang; Guangyu Wang; Jiajia Xu; Yanlin Li; Qing Guo; Tongsen Zheng; Yanqiao Zhang
Journal:  Oncotarget       Date:  2016-12-27

10.  68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.

Authors:  Jasmine Shell; Xavier M Keutgen; Corina Millo; Naris Nilubol; Dhaval Patel; Samira Sadowski; Myriem Boufraqech; Lily Yang; Roxanne Merkel; Christine Atallah; Peter Herscovitch; Electron Kebebew
Journal:  Int J Endocr Oncol       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.